Mark Rogge

Mark Rogge, Ph.D.

Adjunct Professor

Department: Pharmaceutics
Business Phone: (352) 273-7851
Business Email: mark.rogge@ufl.edu

Teaching Profile

Courses Taught
2023
PHA6418 Model-Informed Drug Development

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-7632-5851

Publications

2019
Targeting RNA: A Transformative Therapeutic Strategy.
Clinical and translational science. 12(2):98-112 [DOI] 10.1111/cts.12624. [PMID] 30706991.
2018
A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.
CPT: pharmacometrics & systems pharmacology. 7(9):581-592 [DOI] 10.1002/psp4.12323. [PMID] 30043511.
2015
Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
Clinical pharmacology in drug development. 4(3):163-74 [DOI] 10.1002/cpdd.167. [PMID] 27140796.
2012
A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
Journal of clinical pharmacology. 52(6):798-808 [DOI] 10.1177/0091270011407068. [PMID] 21680782.
2011
Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects.
Journal of clinical pharmacology. 51(7):1004-14 [DOI] 10.1177/0091270010377633. [PMID] 20926751.
2007
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.
European journal of clinical pharmacology. 63(7):647-56 [PMID] 17473917.
2003
Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis.
Clinical pharmacology and therapeutics. 73(4):348-65 [PMID] 12709725.

Grants

Apr 2021 – Mar 2023
Takeda Research Agreement – Rogge Contract
Role: Co-Project Director/Principal Investigator
Funding: TAKEDA PHARM NORTH AMERICA

Contact Details

Phones:
Business:
(352) 273-7851
Emails:
Business:
mark.rogge@ufl.edu
Addresses:
Business Mailing:
PO Box 100494
GAINESVILLE FL 32610